---
title: "Tremfya (guselkumab) in plaque psoriasis: Dosing and administration questions"
description: "Dosing and administration questions on Tremfya (guselkumab) in plaque psoriasis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Dosing, Administration, and Before treatment. Questions: What is the Tremfya dose for plaque psoriasis? Does Tremfya dosing change with body weight? Can patients self-inject Tremfya? Where is Tremfya injected? 1 further question follow. 5 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/dosing-and-administration"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Tremfya (guselkumab) in plaque psoriasis: Dosing and administration questions

Manufacturer: Janssen Biotech, Inc.  
Prescribing information: [Tremfya](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf)

Dosing and administration questions that apply to every indication of Tremfya are on [Tremfya (guselkumab), all indications: Dosing and administration](https://www.evicenter.com/medical-information/tremfya/dosing-and-administration).

## Dosing

<a id="tremfya-dose"></a>

### What is the Tremfya dose for plaque psoriasis?

> “TREMFYA<sup>®</sup> is administered by subcutaneous injection at Week 0, Week 4, and every 8 weeks thereafter.”

Source: [TREMFYA: Moderate To Severe Pediatric Plaque PsO, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/pediatric/#:~:text=is%20administered%20by%20subcutaneous%20injection,and%20every%208%20weeks%20thereafter.)

> “The recommended dose for adults and pediatric patients 6 years of age and older who also weigh at least 40 kg is 100 mg.”

Source: [TREMFYA: Moderate To Severe Pediatric Plaque PsO, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/pediatric/#:~:text=The%20recommended%20dose%20for%20adults,40%20kg%20is%20100%20mg.)

> “One 100-mg injection
> on day 1
>
> Then 1 injection
> 4 weeks later
>
> Then 1 injection
> every 8 weeks thereafter”

Source: [TREMFYA: Dosing: Moderate to Severe Plaque PsO, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/dosing/#:~:text=One%20100%2Dmg%20injection,every%208%20weeks%20thereafter)

<a id="tremfya-body-weight"></a>

### Does Tremfya dosing change with body weight?

Applies to: Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

> “Clearance and volume of distribution of guselkumab 
> increases as body weight increases, however, observed clinical trial data indicate 
> that dose adjustment for body weight is not warranted.”

Source: [TREMFYA: Prescribing information, page 6, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf#page=6)

> “Examination of age, gender, race, body weight, and previous treatment with 
> systemic or biologic agents did not identify differences in response to TREMFYA 
> among these subgroups.”

Source: [TREMFYA: Prescribing information, page 8, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf#page=8)

## Administration

<a id="tremfya-self-injection"></a>

### Can patients self-inject Tremfya?

> “TREMFYA<sup>®</sup> is intended for use under the guidance and supervision of a healthcare professional. After proper training in subcutaneous injection technique, adults may self-inject. Pediatric self-administration is not recommended. Administration of TREMFYA<sup>®</sup> to pediatric patients should be performed by a healthcare provider or by a caregiver who has received training and demonstrated proper subcutaneous injection technique.”

Source: [TREMFYA: Dosing: Moderate to Severe Plaque PsO, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/dosing/#:~:text=is%20intended%20for%20use%20under,demonstrated%20proper%20subcutaneous%20injection%20technique.)

<a id="tremfya-injection-sites"></a>

### Where is Tremfya injected?

> “Adults may self-inject with the TREMFYA prefilled syringe, One-Press 
> injector, and prefilled pen. 
>
> °	 Inject into the front of the thighs, the lower abdomen except for the 
> 2 inches around the navel, or the back of the upper arms (healthcare 
> professional or caregiver only).”

Source: [TREMFYA: Prescribing information, page 2, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf#page=2)

> “Pediatric Patients 6 Years of Age and Older Who Also Weigh at Least 40 kg
>
> °	 Pediatric self-administration is not recommended. Administration of 
> TREMFYA to pediatric patients with the prefilled syringe, One-Press 
> injector and prefilled pen should be performed by a healthcare provider 
> or by a caregiver who has received training and demonstrated proper 
> subcutaneous injection technique.
>
> °	 Inject into the front of the thighs or the lower abdomen except for the 
> 2 inches around the navel. For the prefilled syringe only, injection can 
> also be given in the back of the upper arms.”

Source: [TREMFYA: Prescribing information, page 2, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf#page=2)

> “Do not inject TREMFYA into areas where the skin is tender, bruised, red, hard, 
> thick, scaly, or affected by psoriasis [see Instructions for Use].”

Source: [TREMFYA: Prescribing information, page 2, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf#page=2)

## Before treatment

<a id="tremfya-pretreatment-tests"></a>

### What tests are needed before starting Tremfya?

> “Pretreatment Evaluation: Evaluate for tuberculosis (TB) infection; if clinically indicated, evaluate liver enzymes and bilirubin levels. Complete all age-appropriate vaccinations according to current immunization guidelines.
>
> Monitor: For signs and symptoms of active TB during and after treatment with TREMFYA<sup>®</sup>. If clinically indicated, evaluate liver enzymes and bilirubin levels periodically according to routine patient management.”

Source: [TREMFYA: Dosing: Moderate to Severe Plaque PsO, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/dosing/#:~:text=Pretreatment%20Evaluation%3A%20Evaluate%20for%20tuberculosis,according%20to%20routine%20patient%20management.)

## Related pages
- [Medical information: Tremfya (guselkumab): Plaque psoriasis](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis)
- [Indication](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/safety)
- [Specific populations](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/specific-populations)
- [Access and coverage](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/guidelines)
